Karyopharm Therapeutics (KPTI) EBIAT (2016 - 2025)
Karyopharm Therapeutics (KPTI) has disclosed EBIAT for 14 consecutive years, with -$102.2 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT fell 232.03% year-over-year to -$102.2 million, compared with a TTM value of -$213.6 million through Dec 2025, down 166.26%, and an annual FY2025 reading of -$196.0 million, down 156.52% over the prior year.
- EBIAT was -$102.2 million for Q4 2025 at Karyopharm Therapeutics, down from -$33.1 million in the prior quarter.
- Across five years, EBIAT topped out at $38.7 million in Q4 2021 and bottomed at -$102.2 million in Q4 2025.
- Average EBIAT over 5 years is -$36.3 million, with a median of -$36.8 million recorded in 2022.
- The sharpest move saw EBIAT skyrocketed 189.17% in 2021, then plummeted 247.12% in 2025.
- Year by year, EBIAT stood at $38.7 million in 2021, then crashed by 199.45% to -$38.5 million in 2022, then fell by 8.65% to -$41.8 million in 2023, then rose by 26.43% to -$30.8 million in 2024, then plummeted by 232.03% to -$102.2 million in 2025.
- Business Quant data shows EBIAT for KPTI at -$102.2 million in Q4 2025, -$33.1 million in Q3 2025, and -$35.0 million in Q2 2025.